Συγγραφείς:
Tsivgoulis, G.
Katsanos, A.H.
Voumvourakis, K.
Hadjigeorgiou, G.M.
Heliopoulos, I.
Karapanayiotides, T.
Papathanasopoulos, P.
Kilidireas, C.
Grigoriadis, N.
Λέξεις-κλειδιά:
alemtuzumab; beta1a interferon; glatiramer; natalizumab; ocrelizumab; glatiramer, clinical effectiveness; drug efficacy; human; immunotherapy; Letter; methodology; monotherapy; multiple sclerosis; randomized controlled trial (topic); therapy effect; treatment outcome; multiple sclerosis, Glatiramer Acetate; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting